Literature DB >> 16083968

The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy.

Karl O A Yu1, Steven A Porcelli.   

Abstract

CD1d-restricted NKT cells have been identified as an important component of the immune system that have the capacity both to augment beneficial host immunity and to prevent harmful autoimmunity. These cells have the ability to produce a wide variety of cytokines, including both proinflammatory and antiinflammatory cytokines that can have multiple different effects on the outcome of immune reactions. The discovery that these T cells are activated by specific recognition of glycolipids in the glycosylceramide family has led to new approaches to manipulate the pleiotropic functions of these cells. Here, we review the multiple activities that have been attributed to NKT cells in a variety of different disease models, and the current state of our understanding of the mechanisms that control the functional outcome of NKT cell activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083968     DOI: 10.1016/j.imlet.2005.06.010

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  50 in total

1.  Natural killer T cells: know thyself.

Authors:  Mitchell Kronenberg; Laurent Gapin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

2.  Synthesis and evaluation of 3''- and 4''-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000.

Authors:  Ravinder Raju; Bernard F Castillo; Stewart K Richardson; Meena Thakur; Ryan Severins; Mitchell Kronenberg; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2009-06-06       Impact factor: 2.823

3.  Role of 2B4-mediated signals in the pathogenesis of a murine hepatitis model independent of Fas and Valpha14 NKT cells.

Authors:  Hiroshi Furukawa; Hiroshi Kitazawa; Izumi Kaneko; Mitsunobu Matsubara; Masato Nose; Masao Ono
Journal:  Immunology       Date:  2008-09-17       Impact factor: 7.397

Review 4.  NKT cells in sepsis.

Authors:  Briana Leung; Hobart W Harris
Journal:  Clin Dev Immunol       Date:  2010-10-04

5.  T helper type 2-polarized invariant natural killer T cells reduce disease severity in acute intra-abdominal sepsis.

Authors:  R V Anantha; D M Mazzuca; S X Xu; S A Porcelli; D D Fraser; C M Martin; I Welch; T Mele; S M M Haeryfar; J K McCormick
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

6.  Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells.

Authors:  Barbara A Sullivan; Niranjana A Nagarajan; Gerhard Wingender; Jing Wang; Iain Scott; Moriya Tsuji; Richard W Franck; Steven A Porcelli; Dirk M Zajonc; Mitchell Kronenberg
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 7.  Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.

Authors:  Manjunatha M Venkataswamy; Steven A Porcelli
Journal:  Semin Immunol       Date:  2009-11-27       Impact factor: 11.130

8.  Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin.

Authors:  Manjunatha M Venkataswamy; Andres Baena; Michael F Goldberg; Gabriel Bricard; Jin S Im; John Chan; Faye Reddington; Gurdyal S Besra; William R Jacobs; Steven A Porcelli
Journal:  J Immunol       Date:  2009-08-01       Impact factor: 5.422

9.  Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.

Authors:  Joanne E Croudace; Stuart M Curbishley; Manuela Mura; Carrie R Willcox; Petr A Illarionov; Gurdyal S Besra; David H Adams; David A Lammas
Journal:  BMC Immunol       Date:  2008-12-03       Impact factor: 3.615

10.  Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.

Authors:  Jin S Im; Pooja Arora; Gabriel Bricard; Alberto Molano; Manjunatha M Venkataswamy; Ian Baine; Elliot S Jerud; Michael F Goldberg; Andres Baena; Karl O A Yu; Rachel M Ndonye; Amy R Howell; Weiming Yuan; Peter Cresswell; Young-Tae Chang; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.